Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome

Eur J Endocrinol. 2012 Dec 10;168(1):67-74. doi: 10.1530/EJE-12-0594. Print 2013 Jan.

Abstract

Context: Primary pigmented nodular adrenocortical disease (PPNAD) can lead to steroid hormone overproduction. Mutations in the cAMP protein kinase A regulatory subunit type 1A (PRKAR1A) are causative of PPNAD. Steroidogenesis in PPNAD can be modified through a local glucocorticoid feed-forward loop.

Objective: Investigation of regulation of steroidogenesis in a case of PPNAD with virilization.

Materials and methods: A 33-year-old woman presented with primary infertility due to hyperandrogenism. Elevated levels of testosterone and subclinical ACTH-independent Cushing's syndrome led to the discovery of an adrenal tumor, which was diagnosed as PPNAD. In vivo evaluation of aberrantly expressed hormone receptors showed no steroid response to known stimuli. Genetic analysis revealed a PRKAR1A protein-truncating Q28X mutation. After adrenalectomy, steroid levels normalized. Tumor cells were cultured and steroidogenic responses to ACTH and dexamethasone were measured and compared with those in normal adrenal and adrenocortical carcinoma cells. Expression levels of 17β-hydroxysteroid dehydrogenase (17β-HSD) types 3 and 5 and steroid receptors were quantified in PPNAD, normal adrenal, and adrenal adenoma tissues.

Results: Isolated PPNAD cells, analogous to normal adrenal cells, showed both increased steroidogenic enzyme expression and steroid secretion in response to ACTH. Dexamethasone did not affect steroid production in the investigated types of adrenal cells. 17β-HSD type 5 was expressed at a higher level in the PPNAD-associated adenoma compared with control adrenal tissue.

Conclusion: PPNAD-associated adenomas can cause virilization and infertility by adrenal androgen overproduction. This may be due to steroidogenic control mechanisms that differ from those described for PPNAD without large adenomas.

Publication types

  • Case Reports
  • Research Support, N.I.H., Intramural

MeSH terms

  • 17-Hydroxysteroid Dehydrogenases / metabolism
  • Adenoma / complications
  • Adenoma / physiopathology
  • Adenoma / surgery
  • Adrenal Cortex Diseases / complications
  • Adrenal Cortex Diseases / physiopathology*
  • Adrenal Cortex Diseases / surgery
  • Adrenal Glands / metabolism*
  • Adrenocortical Adenoma / complications*
  • Adrenocortical Adenoma / physiopathology
  • Adrenocortical Adenoma / surgery
  • Adrenocorticotropic Hormone / physiology
  • Adult
  • Cushing Syndrome
  • Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / genetics*
  • Female
  • Humans
  • Testosterone / blood
  • Virilism / etiology*

Substances

  • Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • PRKAR1A protein, human
  • Testosterone
  • Adrenocorticotropic Hormone
  • 17-Hydroxysteroid Dehydrogenases